Panserin 413: Serum-Free Medium for Lymphocytes, T Cells, and Hybridoma Cells, w: L-Glutamine, modified

Introduction

PAN-Biotech Panserin 413 is a ready-to-use, serum-free, low protein (<0.1% w/v) and low animal-derived components (< 0.6%) medium for the serum-free cultivation and proliferation of lymphocytes from whole blood. The medium can be used for the enrichment of T cells , cytokine-induced killer (CIK) cells, lymphokine-activated killer (LAK) cells, and natural killers (NK) cells. It allows:

• Expansion of T-Cells from PBMC / whole blood after stimulation (e.g. with PHA-L or anti-CD3).
• Expansion of NK-, LAK- and CIK-cells after stimulation.
• Long-term cultivation of immortalized T-cells.

Composition

This defined formulation based on RPMI 1640 and DMEM/F12 is optimized with additional salts, trace elements, albumin, cholesterol, lipids and vitamins. The medium contains no hydrolysates, and only traces of animal-derived components (< 0.6% w/v) and proteins (< 0.1% w/v). IMPORTANT: Mitogens, such as PHA-L, or antibodies, such as CD3+, are necessary for the cell differentiation or the enrichment of T-cells from whole blood/PBMC. These reagents are not included.

Application

Panserin 413 modified is a ready-to-use medium optimized for the serum-free in vitro cultivation of human immune cells isolated from peripheral whole blood. The Panserin 413 modified formulation allows the efficient expansion of T-cells, CIK, LAK, and NK cells without the addition of bovine serum or (autologous) human serum.

For isolation of PBMCs / lymphocytes from whole blood by density gradient centrifugation, we recommend using Pancoll Human: Cell Separating Solution, Density 1.077 g/ml.

Documents

• Product Datasheet (PDS)
• Material Safety Data Sheet (MSDS)

Product References

• Taghizadeh Shool, Maryam et al. “Investigating the Cytotoxicity of Ru(II) Polypyridyl Complexes by Changing the Electronic Structure of Salicylaldehyde Ligands.” Inorganic chemistry vol. 63,2 (2024): 1083-1101. doi:10.1021/acs.inorgchem.3c03414
• Boulos, Joelle C et al. “Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma.” Acta pharmacologica Sinica vol. 44,11 (2023): 2265-2281. doi:10.1038/s41401-023-01117-3
• Kropp, Korbinian N et al. “Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.” Frontiers in immunology vol. 14 1245559. 2 Oct. 2023, doi:10.3389/fimmu.2023.1245559
• Boulos, Joelle C et al. “In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.” Cancers vol. 15,16 4136. 16 Aug. 2023, doi:10.3390/cancers15164136
• Di Pietro, Maria Letizia et al. “Antileukemia Activity and Mechanism of Platinum(II)-Based Metal Complexes.” Molecules (Basel, Switzerland) vol. 27,24 9000. 17 Dec. 2022, doi:10.3390/molecules27249000
• Saeed, Mohamed E M et al. “In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF-κB Inhibitors.” International journal of molecular sciences vol. 23,7 3966. 2 Apr. 2022, doi:10.3390/ijms23073966
• Boulos, Joelle C et al. “Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells.” Pharmaceuticals (Basel, Switzerland) vol. 14,11 1126. 5 Nov. 2021, doi:10.3390/ph14111126
• Özenver, Nadire et al. “Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells.” Molecules (Basel, Switzerland) vol. 25,14 3224. 15 Jul. 2020, doi:10.3390/molecules25143224
• El-Daher, Marie-Therese et al. “Tetratricopeptide repeat domain 7A is a nuclear factor that modulates transcription and chromatin structure.” Cell discovery vol. 4 61. 13 Nov. 2018, doi:10.1038/s41421-018-0061-y
• Özenver, Nadire et al. “Aloe-emodin as drug candidate for cancer therapy.” Oncotarget vol. 9,25 17770-17796. 3 Apr. 2018, doi:10.18632/oncotarget.24880
• Saeed, Mohamed E M et al. “Molecular Determinants of Sensitivity or Resistance of Cancer Cells Toward Sanguinarine.” Frontiers in pharmacology vol. 9 136. 26 Feb. 2018, doi:10.3389/fphar.2018.00136

Related Products

• PAN-Biotech Phytohemagglutinin-L (PHA-L), Lyophilized
  
• Pancoll Human: Cell Separating Solution, Density 1.077 g/ml

Ilex Life Sciences LLC is an authorized distributor of PAN-Biotech products.